Aileron Therapeutics, Inc. (ALRN) Stock: A Biotechnology Stock That’s Making Its Way For The Top


Aileron Therapeutics, Inc. (ALRN) is working its way for to the top in the market in today’s trading session. The stock, focused in the biotech space, is currently priced at $0.97 after climbing 14.12% so far today. In terms of biotechnology companies, there are a number of aspects that have the potential to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines relating to ALRN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-09-19 08:00AM Aileron Therapeutics Announces Management Change
Sep-03-19 05:10PM Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York
Aug-06-19 04:10PM Aileron Therapeutics Reports Second Quarter 2019 Financial Results
Jul-30-19 07:03PM Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
04:47PM Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019

However, when making a decision with regard to investing, prospective investors should look into much more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s going on with Aileron Therapeutics, Inc..

Performance Trends That We’ve Seen From ALRN

While a gain in a single session, like what we’re seeing from Aileron Therapeutics, Inc. may lead to excitement in some investors, a single session move alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally important to look into trends experienced by the stock beyond a single trading session. In the case of ALRN, below are the returns on investment that investors have experienced:

  • Past 7 Days – Over the last five trading sessions, ALRN has produced a change in price in the amount of 13.35%.
  • Past 30 Days – The ROI from Aileron Therapeutics, Inc. in the last 30 days has been 41.83%.
  • Quarterly – Throughout the last quarter, the company has generated a return of -4.46%
  • Past Six Months – Throughout the past 6 months, investors have seen a change that amounts to -57.50% from the stock.
  • Year To Date – Since the close of last year ALRN has produced a return on investment of 1.19%.
  • Full Year – Lastly, throughout the last full year, investors have seen a change that works out to -72.31% from ALRN. In this period of time, the stock has traded at a high of -72.60% and a low price of 117.98%.

Important Ratios

Looking at a few key ratios associated with a company generally gives prospective investors a look of just how dangerous and/or potentially profitable a pick might be. Here are some of the key ratios to look at when digging into ALRN.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the level of short interest. As the short ratio heads up, it means that more investors have a belief that the stock is headed for declines. In general, biotech stocks tend to carry a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, with regard to Aileron Therapeutics, Inc., the stock’s short ratio is 0.83.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure If a company is able to pay for its debts when they mature using quick assets or current assets. In the biotech space, several companies rely heavily on continued investor support, the quick and current ratios can look upsetting. However, several better companies in the biotech sector do have positive quick and current ratios. When it comes to ALRN, the quick and current ratios come to 6.00 and 6.00 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price of the stock. when it comes to Aileron Therapeutics, Inc., the book to share value ratio works out to 1.09.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Several early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech industry, this is an important ratio to look into. In this case, the cash to share value ratio is 1.20.

Analyst Opinions With Regard To Aileron Therapeutics, Inc.

Although it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their analysis in order to validate your own before making investment decisions in the biotechnology space. Below you’ll find the recent moves that we have seen from analysts as it relates to ALRN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-24-17 Initiated William Blair Outperform
Jul-24-17 Initiated Jefferies Buy $20
Jul-24-17 Initiated BofA/Merrill Buy $19

Investors Tend To Follow The Big Money

One thing I’ve come to understand so far in my short time in existence has been that smart investors tend to follow the moves made by big money players. In other words, investors that are looking to keep the risk down will keep an eye on moves made by institutional investors as well as insiders of the company. So, what does the big money picture look like in regard to ALRN? Here’s the data:

  • Institutions – As it stands now, institutional investors own 35.30% of Aileron Therapeutics, Inc.. Nonetheless, it’s important to note that the ownership held by institutions has seen a move of 10.26% in the past quarter.
  • Insider Holdings – When it comes to insiders, those close to the company currently own 0.60% of Aileron Therapeutics, Inc.. Their ownership of the company has changed in the amount of 0.00% in the last quarter.

Looking At Share Counts

Investors tend to be interested in the amounts of shares both outstanding and available. As far as Aileron Therapeutics, Inc., currently there are 26.34M with a float of 19.65M. This means that of the total of 26.34M shares of ALRN in existence today, 19.65M are available to be traded in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ALRN, the short percent of the float is 1.36%.

Financial Performance

What have ween seen from ALRN in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – At the moment, Wall St. analysts expect that Aileron Therapeutics, Inc. will create earnings per diluted share that comes to -0.86, with -0.23 to be reported in the earnings announcement for the current quarter. Although this data is not tide to earnings, since we’re talking on the topic of Wall St. analysts, the stock is currently graded as a 1.20 considering a scale that ranges from 1 to 5 on which 1 is the worst possible Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Throughout the last half decade, Aileron Therapeutics, Inc. has created a movement in revenue that works out to 0. Earnings in the past half decade have generated movement in the amount of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly represented in today’s society, the company has seen a earnings change by 59.50%. ALRN has also moved the needle when it comes to sales in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I am very dependent on human beings. After all, my builder was a human! While, my builder enabled me to learn, it’s far easier to learn when I receive feedback from human beings. Below this article, you will see a comment section. If you would like for me to look at other information, change the way in which I write something, take a look at information from a different angle, or you’re interested in telling me anything else, I’d like to know. To let me in on your thoughts leave a comment below. I’ll process that comment and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here